SCHEMBL5306342

SCHEMBL5306342

O=C(O)c1ccc(F)c2cccnc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.59
L3MBTL1 Q9Y468 6/20 0.59
MPI P34949 1/20 0.59
KDM4A O75164 2/20 0.58
EGLN1 Q9GZT9 2/20 0.58
KDM6B O15054 1/20 0.58
KDM6A O15550 1/20 0.58
TET3 O43151 1/20 0.58
KDM4B O94953 1/20 0.58
KDM5C P41229 1/20 0.58
KDM4D Q6B0I6 1/20 0.58
TET2 Q6N021 1/20 0.58
ALKBH5 Q6P6C2 1/20 0.58
TET1 Q8NFU7 1/20 0.58
FTO Q9C0B1 1/20 0.58
KDM4C Q9H3R0 1/20 0.58
KDM2A Q9Y2K7 1/20 0.58
KDM3A Q9Y4C1 1/20 0.58
NAPRT Q6XQN6 2/20 0.53
SLC40A1 Q9NP59 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4033083 0.86 KDM4E (0.68) KDM4EL3MBTL1MPIKDM4AEGLN1
SCHEMBL69673 0.85 KDM4E (0.77) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL18689122 0.81 KDM4E (0.62) KDM4EL3MBTL1MPIKDM4AEGLN1
SCHEMBL11261836 0.81 KDM4E (0.75) KDM4EL3MBTL1MPIKDM4AEGLN1
SCHEMBL1126280 0.79 KMT2A (0.62) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL30503371 0.79 SLC6A2 (0.59) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL28507152 0.79 KDM4E (0.59) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL11803761 0.79 SLC6A2 (0.59) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL29848459 0.79 HSP90AA1 (0.59) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL3131493 0.79 HSP90AA1 (0.59) KDM4EL3MBTL1KDM4AEGLN1KDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11053215-B2 Heterocyclic compounds useful as Pim kinase inhibitors INCYTE CORPORATION (US) 2021-07-06 US disclosed
US-10450296-B2 Heterocyclic compounds useful as Pim kinase inhibitors INCYTE CORPORATION (US) 2019-10-22 US disclosed
US-20180282302-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION 2018-10-04 US disclosed
US-9920032-B2 Heterocyclic compounds useful as pim kinase inhibitors INCYTE CORPORATION (US) 2018-03-20 US disclosed
US-20170096411-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION 2017-04-06 US disclosed
WO-2007028789-A1 QUINAZOLINE DERIVATIVES AS ANTIVIRAL AGENTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-03-15 WO disclosed
WO-2007028789-A1 QUINAZOLINE DERIVATIVES AS ANTIVIRAL AGENTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180282302-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 KDM4E 1497/4885L3MBTL1 1056/4885MPI 266/4885
US-11053215-B2 Heterocyclic compounds useful as Pim kinase inhibitors PIM1, PIM2, PIM3 KDM4E 1497/4885L3MBTL1 1056/4885MPI 266/4885
US-10450296-B2 Heterocyclic compounds useful as Pim kinase inhibitors PIM1, PIM2, PIM3 KDM4E 1497/4885L3MBTL1 1056/4885MPI 266/4885
US-20170096411-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 KDM4E 1497/4885L3MBTL1 1056/4885MPI 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.